THE ECONOMICS AND COST-EFFECTIVENESS OF CRITICAL CARE MEDICINE

[1] ASHBY JL, 1993, INQUIRY, V20, P362

[2] BAMS JL, 1985, INTENS CARE MED, V11, P234

[3] BERENSON RA, 1984, CLIN OUTCOMES COSTS

[4] COST-CONTAINMENT IN CRITICAL CARE [J]. CRITICAL CARE MEDICINE, 1986, 14 (12) : 1068 - 1077

[5] SEPSIS SYNDROME - A VALID CLINICAL ENTITY [J]. CRITICAL CARE MEDICINE, 1989, 17 (05) : 389 - 393

[6] Chalfin D B, 1994, New Horiz, V2, P275

[7] THE ECONOMIC-IMPACT AND COST-EFFECTIVENESS OF MONOCLONAL-ANTIBODY THERAPY FOR SEPSIS [J]. CLINICAL INFECTIOUS DISEASES, 1993, 17 : S520 - S524

[8] COST-EFFECTIVENESS OF MONOCLONAL-ANTIBODIES TO GRAM-NEGATIVE ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS IN ICU PATIENTS [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (02): : 249 - 254

[9] Chang RWS, 1993, CLIN INTENSIVE CARE, V4, P208

[10] CHASSIN M, 1982, MED CARE, V2, P1282

[1] ASHBY JL, 1993, INQUIRY, V20, P362

[2] BAMS JL, 1985, INTENS CARE MED, V11, P234

[3] BERENSON RA, 1984, CLIN OUTCOMES COSTS

[4] COST-CONTAINMENT IN CRITICAL CARE [J]. CRITICAL CARE MEDICINE, 1986, 14 (12) : 1068 - 1077

[5] SEPSIS SYNDROME - A VALID CLINICAL ENTITY [J]. CRITICAL CARE MEDICINE, 1989, 17 (05) : 389 - 393

[6] Chalfin D B, 1994, New Horiz, V2, P275

[7] THE ECONOMIC-IMPACT AND COST-EFFECTIVENESS OF MONOCLONAL-ANTIBODY THERAPY FOR SEPSIS [J]. CLINICAL INFECTIOUS DISEASES, 1993, 17 : S520 - S524

[8] COST-EFFECTIVENESS OF MONOCLONAL-ANTIBODIES TO GRAM-NEGATIVE ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS IN ICU PATIENTS [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (02): : 249 - 254

[9] Chang RWS, 1993, CLIN INTENSIVE CARE, V4, P208

[10] CHASSIN M, 1982, MED CARE, V2, P1282